To retrospectively analyze the clinical characteristics of children with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, this study involved 739 children with SARS-CoV-2 infection who were admitted to multiple medical institutions in Zhuhai City from December 15, 2022 to January 24, 2023. Epidemiological and clinical data were collected and analyzed using statistical methods to understand the disease characteristics. The onset and progression of SARS-CoV-2 infection in children were significantly associated with age distribution, basic illness, vaccination status, exposure history, and family clustering. The most common clinical symptoms were fever (91.7%) and cough (81.6%). Laboratory findings indicated elevated neutrophil count, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, prothrombin time, and procalcitonin, creatine kinase, D-dimer, and IL-6 levels, along with decreased lymphocyte count, platelet count, and lymphocyte-to-monocyte ratio. Lung computed tomography (CT) showed imaging changes strongly linked to severe infection. After receiving anti-inflammatory, symptomatic, supportive, and antipathogen therapies, 74% of the children displayed clinical symptomatic relief, 26% of the children were cured and discharged, and there were no fatalities. In Zhuhai, children infected with SARS-CoV-2 commonly exhibit family-based transmission, with fever and cough as the predominant symptoms. Factors, such as young age, basic illness, specific laboratory markers, and patchy exudative changes on lung CT scans, served as critical indicators of severe infection. Early detection and monitoring of these factors, along with timely vaccination against novel coronavirus, can mitigate disease severity and prevent progression.
| [1] |
P. Han, L. Li, S. Liu, Q. Wang, and P. Wang, “Receptor Binding and Complex Structures of Human ACE2 to Spike RBD From Omicron and Delta SARS-CoV-2,” Cell 185, no. 4 (2022): 630–640. e10.
|
| [2] |
K. P. Y. Hui, J. C. W. Ho, M. C. Cheung, et al., “SARS-CoV-2 Omicron Variant Replication in Human Bronchus and Lung Ex Vivo,” Nature 603, no. 7902 (2022): 715–720.
|
| [3] |
R. Jang, Z. Xie, Yi Jiang, et al., “Diagnosis, Treatment and Prevention of 2019 Novel Coronavirus Infection in Children: Experts’Consensus Statement (Third Edition)” [in Chinese], Chinese Journal of Applied Clinical Pediatrics 36, no. 10 (2021): 721–732.
|
| [4] |
National Health Commission, State Administration of Traditional Chinese Medicine, “Diagnostic and Treatment Protocol for Novel Coronavirus Infections (Trial 10th Edition),” Infectious Disease Information 36, no. 1 (2023): 18–25.
|
| [5] |
B. Xia, Y. Wang, X. Pan, et al., “Why Is the SARS-CoV-2 Omicron Variant Milder?,” Innovation (Camb) 3, no. 4 (2022): 100251.
|
| [6] |
H. Yang, “Prevention and Control of Novel Coronavirus Infection Epidemic and Chronic Disease Management” [in Chinese], Chinese General Practice 26, no. 07 (2023): 780–782.
|
| [7] |
J. Wang, M. Jiang, X. Chen, and L. J. Montaner, “Cytokine Storm and Leukocyte Changes in Mild Versus Severe SARS-CoV-2 Infection: Review of 3939 COVID-19 Patients in China and Emerging Pathogenesis and Therapy Concepts,” Journal of Leukocyte Biology 108, no. 1 (2020): 17–41.
|
| [8] |
P. Gao, S. Cai, Q. Liu, M. Du, J. Liu, and M. Liu, “Effectiveness and Safety of SARS-CoV-2 Vaccines Among Children and Adolescents: A Systematic Review and Meta-Analysis,” Vaccines 10, no. 3 (2022): 421.
|
| [9] |
E. Callaway, “Omicron Likely to Weaken COVID Vaccine Protection,” Nature 600, no. 7889 (2021): 367–368.
|
| [10] |
K. De Paris and S. R. Permar, “Routine SARS-CoV-2 Vaccination for All Children,” Immunological Reviews 309, no. 1 (2022): 90–96.
|
| [11] |
W. J. Guan, Z. Y. Ni, Y. Hu, et al., “Clinical Characteristics of Coronavirus Disease 2019 in China,” New England Journal of Medicine 382, no. 18 (2020): 1708–1720.
|
| [12] |
Y. Tian, L. Rong, W. Nian, and Y. He, “Review Article: Gastrointestinal Features in COVID-19 and the Possibility of Faecal Transmission,” Alimentary Pharmacology & Therapeutics 51, no. 9 (2020): 843–851.
|
| [13] |
D. Wang, B. Hu, C. Hu, et al., “Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China,” JAMA 323, no. 11 (2020): 1061–1069.
|
| [14] |
X. Zong, Y. Gu, H. Yu, Z. Li, and Y. Wang, “Thrombocytopenia Is Associated With COVID-19 Severity and Outcome: An Updated Meta-Analysis of 5637 Patients With Multiple Outcomes,” Laboratory Medicine 52, no. 1 (2021): 10–15.
|
| [15] |
N. Chen, M. Zhou, X. Dong, et al., “Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study,” Lancet 395, no. 10223 (2020): 507–513.
|
| [16] |
B. M. Henry, M. H. S. de Oliveira, S. Benoit, M. Plebani, and G. Lippi, “Hematologic, Biochemical and Immune Biomarker Abnormalities Associated With Severe Illness and Mortality in Coronavirus Disease 2019 (COVID-19): A Meta-Analysis,” Clinical Chemistry and Laboratory Medicine 58, no. 7 (2020): 1021–1028.
|
| [17] |
C. D. Russell, A. Parajuli, H. J. Gale, et al., “The Utility of Peripheral Blood Leucocyte Ratios as Biomarkers in Infectious Diseases: A Systematic Review and Meta-Analysis,” Journal of Infection 78, no. 5 (2019): 339–348.
|
| [18] |
B. Zhang, X. Zhou, C. Zhu, et al., “Immune Phenotyping Based on the Neutrophil-To-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With COVID-19,” Frontiers in Molecular Biosciences 7 (2020): 157.
|
| [19] |
C. Huang, Y. Wang, X. Li, et al., “Clinical Features of Patients Infected With 2019 Novel Coronavirus in Wuhan, China,” Lancet 395, no. 10223 (2020): 497–506.
|
| [20] |
H. M. Al Nafea, M. T. Al-Qahtani, F. H. Al Gahtani, and H. Tabassum, “Blood Coagulation, Risk Factors and Associated Complications in COVID-19 Patients in Saudi Arabia: A Retrospective Cohort Study,” Medicine (Baltimore) 102, no. 43 (2023): e35621.
|
| [21] |
F. Wang, M. Qu, X. Zhou, et al., “The Timeline and Risk Factors of Clinical Progression of COVID-19 in Shenzhen, China,” Journal of Translational Medicine 18, no. 1 (2020): 270.
|
| [22] |
A. Aminasnafi, S. Heidari, M. Alisamir, M. Mirkarimi, N. Namehgoshayfard, and S. M. S. Pezeshki, “Hematologic Evaluation of Children With COVID-19 Infection: Mortality Biomarkers,” Clinical Laboratory 68, no. 4 (2022).
|
| [23] |
H. Tezer and T. Bedir Demirdağ, “Novel Coronavirus Disease (COVID-19) in Children,” Turkish Journal of Medical Sciences 50, no. SI-1 (2020): 592–603.
|
| [24] |
Y. N. Duan, Y. Q. Zhu, L. L. Tang, and J. Qin, “CT Features of Novel Coronavirus Pneumonia (COVID-19) in Children,” European Radiology 30, no. 8 (2020): 4427–4433.
|
| [25] |
M. Y. Ng, E. Y. P. Lee, J. Yang, et al., “Imaging Profile of the COVID-19 Infection: Radiologic Findings and Literature Review,” Radiol Cardiothorac Imaging 2, no. 1 (2020): e200034.
|
| [26] |
W. Xia, J. Shao, Y. Guo, X. Peng, Z. Li, and D. Hu, “Clinical and CT Features in Pediatric Patients With COVID-19 Infection: Different Points From Adults,” Pediatric Pulmonology 55, no. 5 (2020): 1169–1174.
|
| [27] |
J. V. Waller, K. K. Lin, M. J. Diaz, et al., “CT Presentations of Adult and Pediatric SARS-CoV-2 Patients: A Review of Early COVID-19 Data,” Radiologia (Engl Ed) 63, no. 6 (2021): 495–504.
|
| [28] |
R. Fadel, A. R. Morrison, A. Vahia, et al., “Early Short-Course Corticosteroids in Hospitalized Patients With COVID-19,” Clinical Infectious Diseases 71, no. 16 (2020): 2114–2120.
|
RIGHTS & PERMISSIONS
2025 The Author(s). Pediatric Discovery published by John Wiley & Sons Australia, Ltd on behalf of Children's Hospital of Chongqing Medical University.
PDF
